Ask AI
`Advancing Inflammatory Bowel Disease Management

CE / CME

Advancing Inflammatory Bowel Disease Management With Precision Medicine and Emerging Data

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: May 08, 2025

Expiration: May 07, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Lewis JD, Parlett LE, Jonsson Funk ML, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165:1197-1205.e2.
  2. Dignass A, Redondo I, Streit P, et al. Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study. Curr Med Res Opin. 2023;39:1695-1705.
  3. van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:93-106.
  4. Dubon-Garcia A, Naessens D, Pollack P, et al., P326 Impact of disease flares on resource use, health-related quality of life and productivity in untreated Crohn’s Disease patients in US: an analysis of national health and wellness survey data. J Crohns Colitis. 2024;18(suppl 1):i714-i715.
  5. Colombel JF, Narula N, Peyrin-Biroulet L. management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152:351-361.e5.
  6. Colombel JF, D'haens G, Lee WJ, et al. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020;14:254-266.
  7. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324-1338.
  8. Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015;13:1042-50.e2.
  9. Agrawal M, Colombel JF. Treat-to-target in inflammatory bowel diseases, what is the target and how do we treat? Gastrointest Endosc Clin N Am. 2019;29:421-436.
  10. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570-1583.
  11. Fanizzi F, D’Amico F, Peyrin-Biroulet L, et al. Treatment targets in IBD: is it time for new strategies? Best Pract Res Clin Gastroenterol. 2025;[Epub ahead of print].
  12. Khan S, Sebastian SA, Parmar MP, et al. Factors influencing the quality of life in inflammatory bowel disease: A comprehensive review. Dis Mon. 2024;70(1S):101672.
  13. Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med (Lausanne). 2021;8:765474.
  14. Lin WC, Chang CW, Chen MJ, et al. Intestinal ultrasound in inflammatory bowel disease: a novel and increasingly important tool. J Med Ultrasound. 2023;31:86-91.
  15. Haas K, Rubesova E, Bass D. Role of imaging in the evaluation of inflammatory bowel disease: How much is too much?. World J Radiol. 2016;8:124-131.
  16. Younis MY, Khan MU, Khan U, et al. The current role of imaging in the diagnosis of inflammatory bowel disease and detection of its complications: a systematic review. Cureus. 2024;16:e73134.
  17. Moy MP, Sauk J, Gee MS. The role of MR enterography in assessing Crohn’s disease activity and treatment response. Gastroenterol Res Pract. 2016;2016:8168695.
  18. Park MJ, Lim JS. Computed tomography enterography for evaluation of inflammatory bowel disease. Clin Ednosc. 2013;46:327-336.
  19. Clough J, Colwill M, Poullis A, et al. Biomarkers in inflammatory bowel disease: a practical guide. Therap Adv Gastroenterol. 2024;17:17562848241251600.
  20. Ananthakrishnan AN, Adler J, Chachu KA, et al. Spotlight: role of biomarkers for Crohn’s disease. Gastroenterology. 2023;165:1403.
  21. Singh S, Ananthakrishnan AN, Nhuyen NH, et al. Spotlight: role of biomarkers for ulcerative colitis. Gastroenterology. 2023;164:375.
  22. Andalucia C, Bentow C, Aure MA, et al. Utility of PR3-ANCA in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2024;30(suppl 1):S00.
  23. ISRCTN registry. PROFILE – personalised medicine in Crohn’s disease. Available at: isrctn.com/ISRCTN11808228. Accessed May 1, 2025.
  24. Infliximab [prescribing information]. Horsham, PA: Janssen; 2025.
  25. Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:415-427.
  26. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779-2789.
  27. Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn's disease. Gastroenterology. 2020;159:139-147.
  28. Wilkens R, Novak KL, Maaser C, et al. Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. Therap Adv Gastroenterol. 2021;14:17562848211006672.
  29. Aladraj H, Abdulla M, Guraya SY, et al. Health-related quality of life of patients treated with biological agents and new small-molecule drugs for moderate to severe Crohn's disease: a systematic review. J Clin Med. 2022;11:3743.
  30. Xu WD, Li R, Huang AF. Role of TL1A in inflammatory autoimmune diseases: a comprehensive review. Front Immunol. 2022 Jul 14;13:891328.
  31. Siegel CA, Leong RW, Anderson JK, et al. Long-term efficacy and safety of intravenous (IV) tulisokibart in patients with Crohn’s disease (CD): results from the open-label extension period of the phase 2 APOLLO-CD study. Presented at: 2024 American College of Gastroenterology; October 25-30, 2024. Abstract P4302.
  32. Sands BE, MA C, Hoque S, et al. Long-term efficacy and safety of intravenous (IV) tulisokibart in patients with ulcerative colitis (UC): results from the open-label extension (OLE) period of the phase 2 ARTEMIS-UC study. Presented at: 2024 American College of Gastroenterology; October 25-30, 2024. Abstract P4359.
  33. Allegretti J, Yarur A, Feagan B, et al. Treatment of moderately to severely active ulcerative colitis with ro7790121 demonstrates early clinical response and symptom improvement – results from the phase 2b TUSCANY-2 trial. Gastroenterology. 2025;168:S17-S18.
  34. Jairath V, Kierkus J, Duvall GA, et al. OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD). J Crohns Colitis. 2025;19(suppl 1):i77-i78.
  35. Reinisch W, Stepek D, Kempinski R, et al. OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD). J Crohns Colitis. 2025;19(suppl 1):i79-i80.